{
  "abstract": "Obesity drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) produce substantial weight loss for patients but do not meaningfully improve their quality of life, and most do not show cardiovascular benefits at one year, shows a meta-analysis of latest trial data published in The BMJ.1",
  "authors": [
    {
      "affiliations": [
        "London"
      ],
      "name": "Ingrid Torjesen"
    }
  ],
  "title": "Most obesity drugs do not improve quality of life or reduce cardiovascular risk, analysis finds",
  "uid": "0be49b47-318e-57df-b118-5dd4f59f1bdb"
}